Paul Edward Kelly Relmada Therapeutics, Inc. (RLMD) insider trading activity

Paul Edward Kelly is Director of RELMADA THERAPEUTICS, INC.. Currently has a direct ownership of 212,295 shares of RLMD, which is worth approximately $696,327. The most recent transaction as insider was on Sep 09, 2024, when has been sold 25,000 shares (Common Stock) at a price of $2.59 per share, resulting in proceeds of $64,750. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 212K

13.35% 3M change

13.35% 12M change

Total Value Held $696,327

Paul Edward Kelly Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Sep 09 2024	BUY Open market or private purchase	$64,750 $2.59 p/Share	25,000 Added 10.54%	212,295 Common Stock
Apr 04 2022	SELL Open market or private sale	$300,400 $30.04 p/Share	10,000 Reduced 5.07%	187,295 Common Stock
Apr 04 2022	BUY Exercise of conversion of derivative security	$32,400 $3.24 p/Share	10,000 Added 4.82%	197,295 Common Stock
Jan 03 2022	SELL Exercise of conversion of derivative security	$64,800 $3.24 p/Share	20,000 Reduced 9.65%	187,295 Common Stock
Mar 09 2021	SELL Open market or private sale	$179,400 $35.88 p/Share	5,000 Reduced 2.9%	167,295 Common Stock
Mar 09 2021	BUY Exercise of conversion of derivative security	$16,200 $3.24 p/Share	5,000 Added 2.82%	172,295 Common Stock
Feb 24 2021	SELL Open market or private sale	$173,150 $34.63 p/Share	5,000 Reduced 2.9%	167,295 Common Stock
Feb 24 2021	BUY Exercise of conversion of derivative security	$16,200 $3.24 p/Share	5,000 Added 2.82%	172,295 Common Stock
Feb 16 2021	BUY Exercise of conversion of derivative security	$30,000 $6.0 p/Share	5,000 Added 2.9%	167,295 Common Stock
Feb 09 2021	SELL Open market or private sale	$72,994 $35.28 p/Share	2,069 Reduced 1.26%	162,295 Common Stock
Feb 08 2021	SELL Open market or private sale	$52,560 $35.04 p/Share	1,500 Reduced 0.9%	164,364 Common Stock
Feb 08 2021	BUY Exercise of conversion of derivative security	$11,564 $3.24 p/Share	3,569 Added 2.11%	165,864 Common Stock
Feb 02 2021	SELL Open market or private sale	$81,118 $35.04 p/Share	2,315 Reduced 1.41%	162,295 Common Stock
Feb 01 2021	SELL Open market or private sale	$1,085 $35.0 p/Share	31 Reduced 0.02%	164,610 Common Stock
Feb 01 2021	BUY Exercise of conversion of derivative security	$56,201 $3.24 p/Share	17,346 Added 9.53%	164,641 Common Stock
Jan 27 2021	SELL Open market or private sale	$163,300 $32.66 p/Share	5,000 Reduced 3.28%	147,295 Common Stock
Jan 27 2021	BUY Exercise of conversion of derivative security	$16,200 $3.24 p/Share	5,000 Added 3.18%	152,295 Common Stock
Jan 26 2021	SELL Open market or private sale	$24,085 $35.16 p/Share	685 Reduced 0.46%	147,295 Common Stock
Jan 25 2021	SELL Open market or private sale	$45,851 $35.27 p/Share	1,300 Reduced 0.87%	147,980 Common Stock
Jan 22 2021	SELL Open market or private sale	$3,758,139 $1789.59 p/Share	2,100 Reduced 1.39%	149,280 Common Stock
Jan 22 2021	BUY Exercise of conversion of derivative security	$13,235 $3.24 p/Share	4,085 Added 2.63%	151,380 Common Stock

PEK

Paul Edward Kelly

Director

New York, NY

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells RLMD shares.

Notify only if

Value

Insider Trading

Get notified when an Relmada Therapeutics, Inc. insider buys or sells RLMD shares.

Notify only if

Operation

Value

Type

News

Receive news related to RELMADA THERAPEUTICS, INC.

Track Activities on RLMD

Account